T-cell receptor (TCR) therapy reprograms immune cells to hunt cancer, and unlike CAR-T it can see fragments of proteins that originate inside a tumour cell and are displayed on its surface - a big advantage for solid tumours, where most of what makes a cell cancerous is hidden. The catch: current TCR products are custom-made from each patient's own cells, a weeks-long, six-figure process, while donor-derived versions risk graft-versus-host disease.

UCLA's answer, reported in Cell Reports Medicine, starts earlier in the pipeline. The team took blood stem cells from donated cord blood, inserted a gene for a receptor targeting NY-ESO-1 - a protein found in many solid tumours - and then grew those stem cells into T cells. Because the receptor is introduced before the cells mature, essentially all of the resulting cells carry the same tumour-targeting receptor instead of a random assortment, removing the need for extra gene editing and the risk that donated cells attack healthy tissue.

The engineered cells, called AlloESO-T, carry a second weapon: natural killer cell receptors that detect stress signals many tumour cells display. That gives the therapy a backup way to kill tumour cells that have shed or hidden the NY-ESO-1 marker - the 'antigen escape' that defeats single-target treatments.

In mouse models of ovarian cancer and melanoma, a single dose kept tumours in check and extended survival without the toxicity seen with conventionally engineered donor T cells; the cells multiplied roughly 100-fold, homed to the tumour and stayed active for weeks. The team says a small number of cord-blood stem cells can yield trillions of therapeutic cells - enough for thousands of doses - in about six weeks, at an estimated $5,000 per dose. The work is preclinical only: the cells have not been tested in humans or approved by regulators.

Sources